NCT03500094View on ClinicalTrials.gov

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

February 2, 2021

Study Completion Date

February 6, 2021

Conditions
Fabry Disease
Interventions
DRUG

Migalastat HCl 150 mg

migalastat HCl 150 mg capsule

Trial Locations (8)

15224

Clinical Study Site, Pittsburgh

22030

Clinical Study Site, Fairfax

30322

Clinical Study Site, Atlanta

33606

Clinical Study Site, Tampa

45229

Clinical Study Site, Cincinnati

55454

Clinical Study Site, Minneapolis

65212

Clinical Study Site, Columbia

NW3 2QG

Clinical Study Site, London

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY